Mylan CEO Heather Bresch may have done her company little favors by arguing it couldn't reduce EpiPen's price, with one analyst telling the firm it needs to get a little contrition and acknowledge its decision to raise the medicine's cost.
Mylan NV CEO Heather Bresch blamed a US health care system that lacks transparency and incentivizes high drug prices for the backlash the company is facing over the high cost of its emergency allergic reaction medicine EpiPen (epinephrine), whose list price has gone up 500% since 2009.
Speaking on CNBC on Aug. 25, Bresch argued that if she reduced the drug's $608 list price, "I couldn't ensure...
The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.
